2024 年第 9 期 第 0 卷

间苯三酚联合生长抑素治疗急性胰腺炎的临床效果研究

Study on the clinical effect of phloroglucinol combined with somatostatin in the treatment of acute pancreatitis

作者：蒋闻弢余瑞杭贾韩静

英文作者：Jiang Wentao Yu Ruihang Jia Hanjing

单位：浙江中医药大学附属第一医院急诊科，杭州310000

英文单位：Department of Emergency the First Affiliated Hospital of Zhejiang Chinese Medicine University Hangzhou 310000 China

关键词：急性胰腺炎；间苯三酚；生长抑素；炎症反应

英文关键词：Acutepancreatitis;Phloroglucinol;Somatostatin;Inflammatoryresponse

• 摘要：

• 目的 探讨间苯三酚联合生长抑素治疗急性胰腺炎（AP）的临床效果。方法 纳入2020年1月至2023年11月在浙江中医药大学附属第一医院就诊并采用间苯三酚联合生长抑素治疗的40例AP患者设为联合组，同期采用生长抑素治疗的40例AP患者设为对照组，收集患者资料行回顾性分析。比较2组临床疗效、临床症状缓解时间及血淀粉酶恢复正常时间、治疗前后炎症因子及血淀粉酶水平、不良反应发生率及死亡率。结果 联合组总有效率高于对照组［95.0%（38/40）比82.5%（33/40）］，差异有统计学意义（χ2=-3.181，P=0.001）。联合组腹痛、恶心呕吐、腹膜刺激征缓解时间及血淀粉酶恢复正常时间均短于对照组［4.00（2.00，4.25）d比6.00（5.00，7.00）d、4.00（2.00，5.00）d比6.00（5.00，7.00）d、2.00（2.00，3.00）d比4.00（3.00，5.00）d、4.00（2.00，6.00）d比6.00（2.75，9.00）d］，差异均有统计学意义（均P<0.05）。治疗后2组肿瘤坏死因子α、白细胞介素6、C反应蛋白及血淀粉酶水平均低于治疗前且联合组均低于对照组（均P<0.05）。联合组和对照组不良反应发生率及死亡率比较差异均无统计学意义［10.0%（4/40）比15.0%（6/40）、2.5%（1/40）比5.0%（2/40）］（均P>0.05）。结论 间苯三酚联合生长抑素治疗AP效果确切，能有效缓解患者临床症状，有效减轻炎症反应，且不会引起较严重的不良反应。

• Objective To investigate the clinical effect of phloroglucinol combined with somatostatin in the treatment of acute pancreatitis(AP). Methods Forty patients with AP who received treatment with combination therapy of phloroglucinol and somatostatin at the First Affiliated Hospital of Zhejiang Chinese Medicine University from January 2020 to November 2023 were included as the combination group, while 40 AP patients treated with somatostatin during the same period were included as the control group. Patients′ data were collected for retrospective analysis. The clinical efficacy, clinical symptom relief time, the recovery time of blood amylase, inflammatory factors and blood amylase levels before and after treatment, adverse reaction incidence and mortality rate were compared between the two groups. Results The total effective rate of the combined group was higher than that of the control group［95.0%(38/40) vs 82.5%(33/40)］, and the difference was statistically significant (χ2=-3.181, P=0.001). The relief time of abdominal pain, nausea and vomiting, peritoneal irritation sign, and the recovery time of blood amylase in the combination group were shorter than those in the control group ［4.00(2.00, 4.25)d vs 6.00(5.00, 7.00)d, 4.00(2.00, 5.00)d vs 6.00(5.00, 7.00)d, 2.00(2.00, 3.00)d vs 4.00(3.00, 5.00)d, 4.00(2.00, 6.00)d vs 6.00(2.75, 9.00)d］, and the differences were statistically significant(all P<0.05). After treatment, the levels of tumor necrosis factor-α, interleukin-6, C-reactive protein, and blood amylase in two groups were all lower than before treatment, and those in combination group were lower than those in control group (all P<0.05). There was no statistically significant difference in the incidence and mortality rates of adverse reactions between the two groups ［10.0%（4/40） vs 15.0%（6/40）, 2.5%（1/40） vs 5.0%（2/40）］(both P>0.05). Conclusion Phloroglucinol combined with somatostatin is effective in the treatment of AP, which can effectively relieve clinical symptoms and inflammatory reaction, and will not cause serious adverse reactions.